Expertise in
41
conditions

Dr. Taiga Nishihori

Internal Medicine
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
22 Years of Experience
Before you request
Expertise in
41
conditions
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Taiga Nishihori is a primary care provider, practicing in Internal Medicine in Tampa, Florida. He has been practicing medicine for over 22 years.

Dr. Nishihori is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Bone Graft, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 284 peer reviewed articles and participating in 18 clinical trials. Dr. Nishihori is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English
Japanese

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Nishihori has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Adult Immune Thrombocytopenia
Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drugs: BMS-986004, Sirolimus, Tacrolimus
Study Phase: Phase 1
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Enrollment Status: Completed
Publish Date: April 02, 2026
Intervention Type: Drug, Procedure
Study Drugs: Pacritinib, Sirolimus, Tacrolimus
Study Phase: Phase 1/Phase 2
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Enrollment Status: Active_not_recruiting
Publish Date: March 02, 2026
Intervention Type: Drug, Other
Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Biological
Study Drug: Gamma Delta T-Cell Infusion
Study Phase: Phase 1
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Fludarabine, Melphalan
Study Phase: Phase 2
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Enrollment Status: Terminated
Publish Date: December 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Enrollment Status: Unknown
Publish Date: February 16, 2023
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Drug
Study Drugs: Selinexor, Liposomal Doxorubicin, Dexamethasone
Study Phase: Phase 1/Phase 2
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: November 14, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: Survivin Vaccine, Prevnar 13, Granulocyte-colony Stimulating Factor
Study Phase: Early Phase 1
View 9 Less Clinical Trials

284 Total Publications

Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
Journal: Blood cancer journal
Published: August 31, 2026
Similar Doctors
Expertise in
24
conditions
Dr. Frederick L. Locke
Internal Medicine
Expertise in
24
conditions
Dr. Frederick L. Locke
Internal Medicine

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-692-4252
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Frederick Locke is a primary care provider, practicing in Internal Medicine in Tampa, Florida. Dr. Locke is highly rated in 24 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Graft, and Bone Marrow Aspiration. Dr. Locke is currently accepting new patients.

Expertise in
22
conditions
Dr. Melissa J. Alsina
Internal Medicine
Expertise in
22
conditions
Dr. Melissa J. Alsina
Internal Medicine

Moffitt Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-663-3488
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Melissa Alsina is a primary care provider, practicing in Internal Medicine in Tampa, Florida. Dr. Alsina is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Aspiration, and Colonoscopy. Dr. Alsina is currently accepting new patients.

Expertise in
41
conditions
Dr. Andrew T. Kuykendall
Hematology Oncology | Internal Medicine
Expertise in
41
conditions
Dr. Andrew T. Kuykendall
Hematology Oncology | Internal Medicine
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-701-3769
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Kuykendall is an Internal Medicine provider practicing medicine in Tampa, Florida. Dr. Kuykendall is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Kuykendall is currently accepting new patients.

Frequently Asked Questions about Dr. Taiga Nishihori

How do I make an appointment with Dr. Taiga Nishihori?

You can book an appointment with Dr. Taiga Nishihori by calling their office at 813-723-4775. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Taiga Nishihori a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Taiga Nishihori is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Taiga Nishihori specialize in?

While Dr. Taiga Nishihori is a Internal Medicine, they have specific expertise in Multiple Myeloma, Graft Versus Host Disease (GvHD), and Chronic Graft Versus Host Disease (cGvHD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Taiga Nishihori participate in research or clinical trials?

Yes. Dr. Taiga Nishihori has published 284 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Taiga Nishihori's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Taiga Nishihori accept my insurance?

Dr. Taiga Nishihori accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-723-4775 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nishihori's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 23 Advanced Conditions
View All 94 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile